Logo
    Search

    Ask Stago (english version)

    Ask Stago: EXPERT ANSWERS TO YOUR EXPERT QUESTIONS

    Ask Stago is the podcast for Hemostasis laboratory professionals.

    In less than 10 minutes, Lisa Gannon and Anne-Cécile Ortega host special guests to provide “expert answers to your expert questions”. Stay abreast of hot topics in Hemostasis through Ask Stago! Contribute to the discussion by sending your questions to ask@stago.com 

    Follow us on LinkedIn and Twitter

    --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    enStago52 Episodes

    Episodes (52)

    S4E4 - Limit of detection (LoD) and limit of quantitation (LoQ): what are we talking about?

    S4E4 - Limit of detection (LoD) and limit of quantitation (LoQ): what are we talking about?

    Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

    In today’s episode, our guest Florence Crépet will help us to understand what is behind the wording “limit of blank”, “limit of detection” and “limit of quantification”, and what it means for the clinical laboratory

    Literature sources:

    • Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008 Aug;29 Suppl 1(Suppl 1):S49-52.
    • CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement  Procedures; Approved  Guideline—Second  Edition. CLSI  document EP17-A2. Wayne,  PA: Clinical and Laboratory  Standards Institute; 2012.
    • CLSI Evaluation of Detection Capability Implementation Guide. CLSI Document EP17-Ed2-IG. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S4E3 - Women at work and Women in Science

    S4E3 - Women at work and Women in Science

    Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

    In this episode, to coincide with International Womens Day (March 8th), we are focusing on Gender equality in the workforce, why this is good for business and good for society overall. We meet with Eva Ohlsson Desormonts, Group HR Director for Stago and Amandine Serret International Business Support and Communications Director for Stago as well as an Executive Coach.

    Literature sources:

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S4E2 - Women’s health series (part 2): Anti-phospholipid syndrome awareness

    S4E2 - Women’s health series (part 2): Anti-phospholipid syndrome awareness

    Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation.

    In today’s episode, we are delighted to speak to April Matera. April experienced a stroke at the age of 39 and from there began her journey towards an anti-phospholipid syndrome diagnosis. Unfortunately it took 7 different visits to 7 different doctors to get her there. She tells us here about her APS road and how it has impacted her life and her dream to have a family.

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S4E1 - Women’s health series (part 1): Women’s health and coagulation

    S4E1 - Women’s health series (part 1): Women’s health and coagulation

    Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation.

    In this series of our new season we will be covering Womens’ health and looking at the broader implications of coagulation and then speaking to a Lupus patient advocate on the impact this disease has had for her personally.

    To start off, in today episode, we are delighted to speak to our Clinical Development Director, Dr Francois Depasse about the broader connection between Womens’ Health and coagulation and then a more in depth look at APS.

    Links to related podcasts:

    Literature sources:

    • https://www.cdc.gov/ncbddd/blooddisorders/women/facts.html
    • Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306
    • Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus anticoagulant/Antiphospholipid antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16: 809-813
    • CLSI Laboratory testing for the Lupus anticoagulant - Approved Guideline. CLSI document H60-A. Wayne, PA; 2014.
    • Devreese, KMJ, de Groot, PG, de Laat, B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020; 18: 2828– 2839. https://doi.org/10.1111/jth.15047 

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S3E12 - Fibrinolysis: the often missed key player of hemostasis

    S3E12 - Fibrinolysis: the often missed key player of hemostasis

    Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

    In today’s episode, our guest Professor Romaric Lacroix will explain us how fibrinolysis is important to the whole hemostasis process and how the sample fibrinolytic activity needs to be evaluated and sometimes monitored.

    Link to previous podcasts:

    Literature sources:

    • Cointe S, Vallier L, Esnault P, Dacos M, Bonifay A, Macagno N, Harti Souab K, Chareyre C, Judicone C, Frankel D, Robert S, Hraiech S, Alessi MC, Poncelet P, Albanese J, Dignat-George F, Lacroix R. Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock. Blood. 2022 Apr 14;139(15):2377-2391.
    • Cointe S, Harti Souab K, Bouriche T, Vallier L, Bonifay A, Judicone C, Robert S, Armand R, Poncelet P, Albanese J, Dignat-George F et Lacroix R. A new assay to evaluate microvesicle plasmin generation capacity: validation in disease with fibrinolysis imbalance. J Extracell Vesicles 2018; Jul 16;7(1):1494482
    • Vallier L, Cointe S, Lacroix R, Bonnifay A, Judicone C, Dignat-George F, Hau C.
    • Kwaan. Microparticle and fibrinolysis. Semin Thromb Hemost. 2017 Mar;43(2):129-134

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S3E11 - What is Factor parallelism for?

    S3E11 - What is Factor parallelism for?

    Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today’s episode, our guest Tom Childs will help us to understand the goal and clinical benefits of the Factor parallelism method.  

    Link to previous podcasts:

    Literature sources:

    • Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006: 432–7 (https://ashpublications.org/hematology/article/2006/1/432/19703/Acquired-Factor-VIII-Inhibitors-Pathophysiology).
    • Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl 6): 20–2.
    • Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7): 2358–63
    • Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011; 41 (6 Suppl 4): S360–8.
    • Collins PW, Chalmers E, Hart D et al.; United Kingdom Haemophilia Centre Doctors’ Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162 (6): 758–73 (https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.12463).
    • Riley PW, Gallea B, Valcour A. Development and implementation of a coagulation factor testing method utilizing autoverification in a high‑volume clinical reference laboratory environment. J Pathol Inform 2017; 8: 25.
    • Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (1): 59–72
    • Oldenburg J, Mahlangu JN, Kim B et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (9): 809–18.
    • Florin L, Desloovere M, Devreese KML. Validation of an automated algorithm for interpretation of lupus anticoagulant testing on the Stago STA R Max (Poster). International Society on Thrombosis and Haemostasis, 2017.

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S3E10 - Pediatric hemostasis: are children “small adults”?

    S3E10 - Pediatric hemostasis: are children “small adults”?

    Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

    In today’s episode, our guest Gabrielle Pearl will explain us the particularities of thrombosis and hemostasis in pediatric population, and how to manage pediatric patient samples in the clinical laboratory.

    Link to previous podcasts:

    • S2E5 - How to collect and prepare the coagulation samples properly?

    https://www.podcastics.com/podcast/episode/s2e5-how-to-collect-and-prepare-the-coagulation-samples-properly-67393/

    • S2E3 - How to establish and control the reference range of my assay?

    https://www.podcastics.com/podcast/episode/s2e3-how-to-establish-and-control-the-reference-range-of-my-assay-60155/

     

    Literature sources:

    • Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, De Rosa L, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Roy N, Rowlands S. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006 Feb;95(2):362-72. doi: 10.1160/TH05-01-0047.
    • Monagle P, Massicotte P. Developmental haemostasis: secondary haemostasis. Semin Fetal Neonatal Med. 2011 Dec;16(6):294-300. doi: 10.1016/j.siny.2011.07.007.
    • Attard C, van der Straaten T, Karlaftis V, Monagle P, Ignjatovic V. Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. J Thromb Haemost 2013; 11: 1850–4.
    • Flanders MM, Phansalkar AR, Crist RA, Roberts WL, Rodgers GM. Pediatric reference intervals for uncommon bleeding and thrombotic disorders. J Pediatr. 2006 Aug;149(2):275-7. doi: 10.1016/j.jpeds.2006.04.008
    • Lippi G, Franchini M, Montagnana M, Guidi GC. Coagulation testing in pediatric patients: the young are not just miniature adults. Semin Thromb Hemost. 2007 Nov;33(8):816-20. doi: 10.1055/s-2007-1000373.

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice

    S3E9 - The importance of Fibrinogen.

    S3E9 - The importance of Fibrinogen.

    Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis.

    In today episode, our expert Lydie Nicoud, R&D reagent manager, will talk with us about the test of fibrinogen. 

    As usual, don’t forget to send any question you may have to ask@stago.com, we will be glad to answer to it.

    Literature sources:

    • Miesbach W, Schenk J, Alesci S, Lindhoff-Last E, Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia .Thromb Res. 2010; 126(6): e428-33
    • Karapetian H. Reptilase time (RT). Methods Mol Bio 2013; 992:273-7.
    • Mackie IJ, Kitchen S, Machin SJ, Lowe GDO, Guidelines on fibrinogen assays, Br J Hematol 2003; 121: 396-404
    • Cunningham MT, Olson JD, Chandler WL, Van Cott EM, Eby CS, Teruya J, Hollensead SC, Adcock DM, Allison PM, Kottke-Marchant KK, Smith MD. External quality assurance of fibrinogen assays using normal plasma: results of the 2008 College of American Pathologists proficiency testing program in coagulation. Arch Pathol Lab Med. 2012 Jul;136(7):789-95. doi: 10.5858/arpa.2011-0322-OA. PMID: 22742551.Siriez R, Dogné JM, Gosselin R, Laloy J, Mullier F, Douxfils J Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory. Int J Lab Hematol 2021; 43(1): 7-20

     

    Related podcasts:

     

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S3E8 - Venoms and coagulation: when evolution reveals useful for drug and assay development.

    S3E8 - Venoms and coagulation: when evolution reveals useful for drug and assay development.

    Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

     

    In today’s episode, our guest Dr Bryan G Fry, aka Venom Doc, will make us enter his world and understand how venom interact with coagulation and how they can prove useful for assay or drug design & development

     

     

    Literature sources:

    • Fry BG, Roelants K, Champagne DE, Scheib H, Tyndall JD, King GF, Nevalainen TJ, Norman JA, Lewis RJ, Norton RS, Renjifo C, de la Vega RC. The toxinogenomic multiverse: convergent recruitment of proteins into animal venoms. Annu Rev Genomics Hum Genet. 2009, 10: 483-511.
    • Bittenbinder, M. A., C. N. Zdenek, B. Op den Brouw, N. J. Youngman, J. S. Dobson, A. Naude, F. J. Vonk and B. G. Fry (2018). "Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib)." Toxins (Basel) 10(12): 516.
    • Chowdhury, A., M. R. Lewin, C. N. Zdenek, R. Carter and B. G. Fry (2021a). "The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra (Naja Species) Venoms." Front Immunol 12: 752442.
    • Seneci, L., C. N. Zdenek, A. Chowdhury, C. F. B. Rodrigues, E. Neri-Castro, M. Benard-Valle, A. Alagon and B. G. Fry (2021). "A Clot Twist: Extreme Variation in Coagulotoxicity Mechanisms in Mexican Neotropical Rattlesnake Venoms." Front Immunol 12: 612846.
    • Chowdhury, A., C. N. Zdenek, J. S. Dobson, L. A. Bourke, R. Soria and B. G. Fry (2021b). "Clinical implications of differential procoagulant toxicity of the palearctic viperid genus Macrovipera, and the relative neutralization efficacy of antivenoms and enzyme inhibitors." Toxicol Lett 340: 77-88.
    • Chowdhury, A., C. N. Zdenek, M. R. Lewin, R. Carter, T. Jagar, E. Ostanek, H. Harjen, M. Aldridge, R. Soria, G. Haw and B. G. Fry (2021). "Venom-Induced Blood Disturbances by Palearctic Viperid Snakes, and Their Relative Neutralization by Antivenoms and Enzyme-Inhibitors." Frontiers in Immunology 12: 2251.
    • Zdenek, C. N., B. O. den Brouw, D. Dashevsky, A. Gloria, N. Youngman, E. Watson, P. Green, C. Hay, N. Dunstan, L. Allen and B. G. Fry (2019a). "Clinical implications of convergent procoagulant toxicity and differential antivenom efficacy in Australian elapid snake venoms." Toxicol Lett 316: 171-182.
    • Zdenek, C. N., C. Hay, K. Arbuckle, T. N. W. Jackson, M. H. A. Bos, B. Op den Brouw, J. Debono, L. Allen, N. Dunstan, T. Morley, M. Herrera, J. M. Gutierrez, D. J. Williams and B. G. Fry (2019b). "Coagulotoxic effects by brown snake (Pseudonaja) and taipan (Oxyuranus) venoms, and the efficacy of a new antivenom." Toxicol In Vitro 58: 97-109.
    • Sousa, L. F., C. A. Nicolau, P. S. Peixoto, J. L. Bernardoni, S. S. Oliveira, J. A. Portes-Junior, R. H. Mourao, I. Lima-dos-Santos, I. S. Sano-Martins, H. M. Chalkidis, R. H. Valente and A. M. Moura-da-Silva (2013). "Comparison of phylogeny, venom composition and neutralization by antivenom in diverse species of bothrops complex." PLoS Negl Trop Dis 7(9): e2442.
    • Rogalski, A., C. Soerensen, B. Op den Brouw, C. Lister, D. Dashevsky, K. Arbuckle, A. Gloria, C. N. Zdenek, N. R. Casewell, J. M. Gutierrez, W. Wuster, S. A. Ali, P. Masci, P. Rowley, N. Frank and B. G. Fry (2017). "Differential procoagulant effects of saw-scaled viper (Serpentes: Viperidae: Echis) snake venoms on human plasma and the narrow taxonomic ranges of antivenom efficacies." Toxicol Lett 280: 159-170.
    • Youngman, N. J., J. Llinas and B. G. Fry (2021). "Evidence for Resistance to Coagulotoxic Effects of Australian Elapid Snake Venoms by Sympatric Prey (Blue Tongue Skinks) but Not by Predators (Monitor Lizards)." Toxins (Basel) 13(9).

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S3E7 - Hemostasis results interpretation along pregnancy.

    S3E7 - Hemostasis results interpretation along pregnancy.

    Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation.

    In today’s episode, our guest François Depasse will help us to understand the hemostasis results obtained along pregnancy, what are the related difficulties for the lab and

    Link to previous podcasts:

    Literature sources:

    • Szecsi PB, Jørgensen M, Klajnbard A, Andresen MR, Colov NP, Stender S, Haemostatic reference intervals in pregnancy. Thromb Haemost 2010; 2013: 718-27
    • Kristoffersen AH, Peters PH, Bjørge L, Røraas T and Sandberg S. Concentration of fibrin monomer in pregnancy and during the postpartum period. Annals of Clinical Biochemistry 2019; 56(6): 692-700.
    • Hellgren H. Hemostasis during normal prgenancy and puerperium. Semin Thromb Hemost. 2003; 29(2): 125-30.
    • Leduc L, Wheeler JM, Kirshon B, Mitchell P, Cotton DB, Coagulation profile in severe preeclampsia, Obstet Gynecol 1992 79(1); 14-8
    • Gillissen A, van den Akker T, Caram-Deelder C, Henriquez DDCA, Bloemenkamp KWM, de Maat MPM, van Roosmalen JJM, Zwart JJ, Eikenboom J, van der Bom JG. Coagulation parameter during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. Blood Adv 2018; 2(19): 2433-42
    • Ducloy-Bouthors AS, Mercier FJ, Grouin JM, Bayoumey F, Corouge I, Le Goueze A, Rackelboom T, Broisin F, Vial F, Luzi A, Capronnier O, Huissoud C, Mignon A, Early and systematic administration of fibrinogen concentrate in post-partum haemorrhage following vaginal delivery: the FIDEL randomized controlled trial. BJOG 2021. 128:1814-23.
    • Brenner A, Ker K, Shakur-Still H, Roberts I. Tranexamic acid for post-partum haemorrhage: what, who and when. Best Pract Res Clin Obstet Gynaecol. 2019; 1:66-74

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S3E6 - IVDR: what is at stake for IVD manufacturers and for the laboratories?

    S3E6 -  IVDR: what is at stake for IVD manufacturers and for the laboratories?

    Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

    In today’s episode, our guest Sophie Réhault will give us explanations on what is the new EU IVD regulation and what it implies both for IVD manufacturers and for the clinical laboratories. 

    Link to previous podcasts: 

     

    Literature sources:

    • Regulation (EU) 2017/746 (IVDR) of the Europan Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and commission Decision 2010/227/EU
    • European Parliament Legislative resolution of 15 December 2021 on te proposal for a regulation of the European Parliament and of the Council amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and deferred application of requirements for in house devices (COM(2021) 0627-C9-0381/2021 – 2021/0323 (COD))
    •  

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S3E5 - Should we handle veterinary citrated blood samples like human ones?

    S3E5 - Should we handle veterinary citrated blood samples like human ones?

    Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

    In today’s episode, our guest Daniel Pilbeam, from the Clinical Pathology Laboratory at UVet in Melbourne will help us understand the common points and differences between veterinary and human hemostasis, and what should be critically assessed.

     

    Previous episodes in relation to the topic:

     

    Literature sources:

    • John W. Harvey, Veterinary Hematology, Chapter 7 - Evaluation of Hemostasis: Coagulation and Platelet Disorders, W.B. Saunders, 2012, Pages 191-233, ISBN 9781437701739, https://doi.org/10.1016/B978-1-4377-0173-9.00007-5.
    • Beurlet S, Coisnon C, Nguyen TT, Richet M, Carlo A, Briend-Marchal A. Comparison of STA-NeoPTimal (Stago) and STA-Neoplastine CI Plus (Stago) thromboplastin reagents using a STA Satellite Max analyzer to measure prothrombin times in dogs. Vet Clin Pathol. 2021 Sep;50(3):348-353. doi: 10.1111/vcp.12949.
    • A previous pathologist, Bruce Parry, also co-wrote a paper that was instrumental in identifying cut offs for factor deficiencies that we still use the reference range for today.

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S3E4 - All you need to know about instrument validation.

    S3E4 - All you need to know about instrument validation.

    Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in coagulation.

    In today’s episode, our guest Kaitlyn Pelc will explain further the different steps to validate an instrument at the installation.

    Previous episodes in relation to the topic:

    Literature sources:

    • CLSI. Protocol for the Evaluation, Validation and Implementation of Coagulometers; Approved Guideline. CLSI document H57-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
    • CLSI. One-Stage Prothrombin Time (PT-Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline- Second Edition. CLSI document H47-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
    • CLSI. Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline. CLSI document H54-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
    • CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline- Third Edition. CLSI document EP28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
    • CLSI. Measurement Procedure Comparison and Bias Estimation Using Patient Samples. 3rd ed. CLSI guideline EP09c. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
    • CLSI. User Verification of Precision and Estimation of Bias; Approved Guideline- Third Edition. CLSI document EP15-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
    • College of American Pathologists.  All Common Checklist. Northfield, IL: College of American Pathologists; 2021.

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S3E3 - Demystifying platelet aggregometry

    S3E3 - Demystifying platelet aggregometry

    Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis.

    In today’s episode, our guest David Courtois will explain further what is platelet aggregometry, how to measure it and in which indications it is useful.

     

    Literature sources:

    • Born GVR. Aggregation of blood platelets by adenosine disphosphate and its reversal. Nature 1962; 194: 927 – 929.
    • O’Brien JR. Platelet aggregation. II. Some results from a new method of study. J Clin Pathol 1962; 15: 452-458.
    • Caen JP, Michel H. Platelet shape change and aggregation. Nature 1972; 240 (5377): 148-149.
    • Holmsen H. Platelet metabolism and activation Semin Hematol. 1985; 22 (3): 2 19-40.
    • Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation in Methods in Hematology, Churchill Livingstone, New-York 1983; 8: 64-91.
    • Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005; 123 (2): 172-183.
    • Hvas AM, Favaloro EJ. Platelet function analyzed by light transmission aggregometry. Methods Mol Biol 2017; 1646: 321-331.
    • Christie DJ, Avari T, Carrington LR, Cohen E, DeBiase BA, Harrison P, Kickler TS, Kottke-Marchant K, Ledford-Kraemer M, Rand ML, Schmaier AH, McCabe White M. Platelet function testing by aggregometry: approved guidelines, H58-A. Clinical and Laboratory Standards Institute: Wayne, PA, USA 2008; 28 (31): 1-45.
    • Frontroth, J.P.; Favaloro, E.J. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies. Methods Mol. Biol. 2017, 1646, 473–494.
    • Hayward CPM, Pai M, Liu Y, Moffat KA, Seecharan J, Weber KE, Cook RJ, Heddle NM. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorders assessments. J Throm Haemost 2009; 7 (4): 676-684
    • Cattaneo M., Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSCC of the ISTH. J. Thromb Haemost 2009; 7: 1029
    • Hayward CPM, Moffat KA, Raby A, Israels S, Plumhoff E, Flynn G, Zehnder J.L. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134: 955-963.
    • Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S. British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155: 30-44
    • Dawood BB, Lowe GC, Lordkipanidze M, Bem D, Daly ME, Makris M, Mumford A, Wilde JT, Watson SP. Evaluation of participants with suspected heritable platelet function disorder including recommendation and validation of a streamlined agonist panel. Blood 2012; 120 (25): 5041-5049.
    • Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D, Nurden P, Rao KA, Schmaier AH, Watson SP, Lussana F, Pugliano MT. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Throm Haemost 2013; 11: 1183-1189.
    • Rao AK. Inherited platelet function disorders: overview and disorders of granules, secretion, and signal transduction. Hematol Oncol Clin North Am 2013; 27 (3): 585-611.
    • Nurden AT, Nurden P. Inherited disorders of platelet function: selected updates. J Thromb Haemost 2015; 13 (Suppl 1): 2-9.
    • Frelinger AL 3rd, Gachet C, Mumford AD, Noris P, Mezzano D, Harrison P, Gresele P. Laboratory monitoring P2Y12 inhibitors communication from the SSC of the ISTH. J Throm Haemost 2018; 16 (11): 2341-2346
    • Podda G, Scavone M, Femia EA, Cattaneo M. Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. Platelets 2018; 29 (7): 644-649.
    • Hayward CPM, Moffat KA, Brunet J, Carlino SA, Plumhoff E, Meijer P, Zehnder JL. Update on diagnostic testing for platelet function disorders: What is pratical and useful? Int J Lab Hematol 2019; 41 (Suppl 1): 26-32
    • Gresele P, Orsini S, Noris P, Falcinelli E, Alleci MC, Bury L, Borhany M, Santoro C, Glembotsky AC, Cid AR, Tosetto A, De Candia E, Fontan P, Guglielmini G, Pecci A, BAT-VAL study investigators (57). Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. J Thromb Haemost 2020; 18 (3): 732:739.
    • Rabbolini D, Connor D, Morel-Kopp MC, Donikian D, Kondo M, Chen W, Alessi MC, Stevenson W, Chen V, Joseph J, Brighton C, Ward C, Sydney Platelet Group. An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group. Pathology 2020; 52 (2): 243-255.

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S3E2 - EQA, a valuable tool for laboratories.

    S3E2 - EQA, a valuable tool for laboratories.

    Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis.

    In today episode, our expert Charlotte Parent, Marketing product manager, will talk with us about the EQA. A valuable tool to ensure the quality of laboratory results.

    As usual, don’t forget to send any question you may have to ask@stago.com, we will be glad to answer to it.

     

    Literature sources:

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.<

    S3E1 - Heparin induced thrombocytopenia: making it clear.

    S3E1 - Heparin induced thrombocytopenia: making it clear.

    Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis.

    In today episode, our expert guest, Dr Caroline Vayne from Tours University Hospital in France, gives us an overview on heparin induced thrombocytopenia.

    As usual, don’t forget to send any question you may have to ask@stago.com, we will be glad to answer to it.

     

    Learn more:

    • Gruel Y, Vayne C, Rollin J, Weber P, Faille D, Bauters A, Macchi L, Alhenc-Gelas M, Lebreton A, De Maistre E, Voisin S, Gouilleux-Gruart V, Perrin J, Tardy-Poncet B, Elalamy I, Lavenu-Bombled C, Mouton C, Biron C, Ternisien C, Nedelec-Gac F, Duchemin J, De Raucourt E, Gouin-Thibault I, Rugeri L, Tardy B, Giraudeau B, Bejan-Angoulvant T, Pouplard C. Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature. Thromb Haemost. 2020 Jul;120(7):1096-1107. doi: 10.1055/s-0040-1712957. Epub 2020 Jun 22. PMID: 32572863.
    • Gruel Y, De Maistre E, Pouplard C, Mullier F, Susen S, Roullet S, Blais N, Le Gal G, Vincentelli A, Lasne D, Lecompte T, Albaladejo P, Godier A; Members of the French Working Group on Perioperative Haemostasis Groupe d’intérêt en hémostase périopératoire GIHP. Diagnosis and management of heparin-induced thrombocytopenia. Anaesth Crit Care Pain Med. 2020 Apr;39(2):291-310. doi: 10.1016/j.accpm.2020.03.012. Epub 2020 Apr 13. PMID: 32299756.
    • Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017 May 25;129(21):2864-2872. doi: 10.1182/blood-2016-11-709873. Epub 2017 Apr 17. PMID: 28416511; PMCID: PMC5445568.
    • Rollin J, Pouplard C, Gruel Y. Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors. Thromb Haemost. 2016 Oct 28;116(5):799-805. doi: 10.1160/TH16-02-0109. Epub 2016 Jun 30. PMID: 27358188.
    • Pishko AM, Cuker A. Diagnosing heparin-induced thrombocytopenia: The need for accuracy and speed. Int J Lab Hematol. 2021 Jul;43 Suppl 1:96-102. doi: 10.1111/ijlh.13564. PMID: 34288442.
    • Tardy B, Lecompte T, Mullier F, Vayne C, Pouplard C. Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia. J Clin Med. 2020 Apr 24;9(4):1226. doi: 10.3390/jcm9041226. PMID: 32344682; PMCID: PMC7230370.
    • Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018 Nov 27;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489. PMID: 30482768; PMCID: PMC6258919.
    • Vayne C, Rollin J, Gruel Y, Pouplard C, Galinat H, Huet O, Mémier V, Geeraerts T, Marlu R, Pernod G, Mourey G, Fournel A, Cordonnier C, Susen S. PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia. N Engl J Med. 2021 Jul 22;385(4):376-378. doi: 10.1056/NEJMc2106383. Epub 2021 May 19. PMID: 34010527; PMCID: PMC8174029.
    • Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Rampotas A, Ambler G, Makris M. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N Engl J Med. 2021 Oct 28;385(18):1680-1689. doi: 10.1056/NEJMoa2109908. Epub 2021 Aug 11. PMID: 34379914.
    • Kizlik-Masson C, Vayne C, McKenzie SE, Poupon A, Zhou Y, Champier G, Pouplard C, Gruel Y, Rollin J. 5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies. J Thromb Haemost 2017; 15: 2065–75.


    Related podcast:

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S2E19 - HTA and value of diagnostic information

    S2E19 - HTA and value of diagnostic information

    Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation.

    In today’s episode, our co-host Audrey Carlo will share her understanding on what is HTA and why Value of Diagnostic Information should be further recognized.

    Literature sources:

    • Wurcel V, Cicchetti A, Garrison L, Kip MMA, Koffijberg H, Kolbe A, Leeflang MMG, Merlin T, Mestre-Ferrandiz J, Oortwijn W, Oosterwijk C, Tunis S, Zamora B. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. Public Health Genomics. 2019;22(1-2):8-15. doi: 10.1159/000501832.
    • Proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.
    •  Porter ME, Teisberg EO, Redefining Health Care: Creating Value-based Competition on Results, Boston, Mass. : Harvard Business School Press, ©2006.

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S2E18 - Practical check list of the implementation of an instrument in your lab

    S2E18 - Practical check list of the implementation of an instrument in your lab

    Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. 

    In today’s episode, our expert Pauline Vasselon, US & Projects Registration Coordinator within Stago Market Access team, will provide us the key steps to implement a new instrument in your laboratory.   

    Literature sources: 

    • ISO 15189 Medical laboratories — Requirements for quality and competence 
    • ISO 22870:2010 Intelligent transport systems — Devices to aid reverse manoeuvres — Extended-range backing aid systems (ERBA) 
    • CLSI Measurement Procedure Comparison and Bias Estimation Using Patient Samples, 3rd Edition, CLSI document EP09c, Wayne PA, 2018. 
    • CLSI Evaluation of Precision of Quantitative Measurement Procedures, Approved guideline, 3rd Edition CLSI document EP05-A3, Wayne PA, 2014. 
    • CLSI Evaluation of Linearity of Quantitative Measurement Procedures, 2nd edition, CLSI document EP06, Wayne PA, 2020. 
    • CLSI Protocol for the Evaluation, Validation, and Implementation of Coagulometers, Approved Guideline, CLSI document H57-A, Wayne PA, 2008. 

     

    Related podcasts:  

    Uncertainty of measurement -

    https://www.podcastics.com/podcast/episode/s2e12-demystifying-measurement-uncertainty-78471/

    Manage lot conversion -

    https://www.podcastics.com/podcast/episode/s2e10-how-to-manage-lot-conversion-in-your-daily-lab-management-75049/

    Manage your pre-analyticals -

    https://www.podcastics.com/podcast/episode/s2e5-how-to-collect-and-prepare-the-coagulation-samples-properly-67393/

    Control the reference ranges of your method -

    https://www.podcastics.com/podcast/episode/s2e3-how-to-establish-and-control-the-reference-range-of-my-assay-60155/

    Manage HIL interferences -

    https://www.podcastics.com/podcast/episode/9-how-to-manage-hil-samples-in-the-coagulation-laboratory-37748/

    Understand the sensitivity and specificity -

    https://www.podcastics.com/podcast/episode/8-what-are-sensitivity-and-specificity-performances-of-a-diagnostic-assay-37747/

    Calculate your MNPT - 

    https://www.podcastics.com/podcast/episode/7-how-to-determine-the-mean-normal-prothrombin-time-37746/

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S2E17 - World Thrombosis Day

    S2E17 - World Thrombosis Day

    Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis.

    In today episode, our expert guest, Dr Stephan Moll, will give a hint of his webinar entitled “The Patient with Venous Thrombosis – Practical Points for the Laboratorian and the Clinician”.

    As usual, don’t forget to send any question you may have to ask@stago.com, we will be glad to answer to it.

    Learn more:

     

    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

    S2E16 - DOAC measurement: how and what for?

    S2E16 - DOAC measurement: how and what for?

    Welcome to Ask Stago, the podcast dedicated to provide expert answers to your expert questions in hemostasis

    In today episode, our expert guest, Jonathan Douxfils, CEO at QUALIblood SA and Professor at the University of Namur / Department of Pharmacy, will detail with us the current recommendation on how to measure direct oral anticoagulants and in which clinical situation this information is relevant and useful..  

    As usual, don’t forget to send any question you may have to ask@stago.com, we will be glad to answer to it. 

    Learn more - Literature sources: 

    • Bernier M, Lancrerot SL, Parassol N, Lavrut T, Viotti J, Rocher F, Drici MD. Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio. J Cardiovasc Pharmacol. 2020 Oct;76(4):472-477. Epub 2020/10/09. doi:10.1097/FJC.0000000000000870. Cited in: Pubmed; PMID 33030858. 
    • Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, Dogne JM, Mullier F. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. Journal of thrombosis and haemostasis : JTH. 2018 Feb;16(2):209-219. Epub 2017/12/02. doi:10.1111/jth.13912. Cited in: Pubmed; PMID 29193737. 
    • Douxfils J, Mullier F, Dogne JM. Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin Drug Saf. 2015 Aug;14(8):1283-9. Epub 2015/05/23. doi:10.1517/14740338.2015.1049995. Cited in: Pubmed; PMID 25994994. 
    • Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thrombosis and haemostasis. 2018 Mar;118(3):437-450. Epub 2018/02/13. doi:10.1055/s-0038-1627480. Cited in: Pubmed; PMID 29433148. 
    • Gosselin RC, Adcock DM, Douxfils J. An update on laboratory assessment for direct oral anticoagulants (DOACs). International journal of laboratory hematology. 2019 May;41 Suppl 1(00):33-39. Epub 2019/05/10. doi:10.1111/ijlh.12992. Cited in: Pubmed; PMID 31069969. 
    • Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. Journal of thrombosis and haemostasis : JTH. 2016 Dec;14(12):2556-2559. Epub 2016/10/25. doi:10.1111/jth.13505. Cited in: Pubmed; PMID 27622661. 
    • Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. Journal of thrombosis and haemostasis : JTH. 2016 Dec;14(12):2559-2561. Epub 2016/10/25. doi:10.1111/jth.13513. Cited in: Pubmed; PMID 27662099. 
    • Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. Journal of thrombosis and haemostasis : JTH. 2016 Jul;14(7):1325-7. Epub 2016/04/21. doi:10.1111/jth.13344. Cited in: Pubmed; PMID 27094864 
    • Douxfils J, Adcock DM, Bates SM, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S, Gosselin RC. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thrombosis and haemostasis. 2021 Mar 19. Epub 2021/03/21. doi:10.1055/a-1450-8178. Cited in: Pubmed; PMID 33742436. 
    • Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, Investigators R-L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). Journal of the American College of Cardiology. 2014 Feb 4;63(4):321-8. Epub 2013/10/01. doi:10.1016/j.jacc.2013.07.104. Cited in: Pubmed; PMID 24076487. 
    • Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. The Lancet. 2015;385(9984):2288-2295. doi:10.1016/s0140-6736(14)61943-7. 
    • Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. JAMA Cardiol. 2017 May 1;2(5):566-574. Epub 2017/03/30. doi:10.1001/jamacardio.2017.0364. Cited in: Pubmed; PMID 28355459. 
    • Bouget J, Oger E. Emergency admissions for major haemorrhage associated with direct oral anticoagulants. Thrombosis research. 2015 Dec;136(6):1190-4. Epub 2015/11/08. doi:10.1016/j.thromres.2015.10.036. Cited in: Pubmed; PMID 26545315. 
    • Pollack CV, Jr., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. The New England journal of medicine. 2017 Aug 3;377(5):431-441. Epub 2017/07/12. doi:10.1056/NEJMoa1707278. Cited in: Pubmed; PMID 28693366. 
    • Sennesael AL, Larock AS, Douxfils J, Elens L, Stillemans G, Wiesen M, Taubert M, Dogne JM, Spinewine A, Mullier F. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thrombosis journal. 2018;16:28. Epub 2018/11/21. doi:10.1186/s12959-018-0183-3. Cited in: Pubmed; PMID 30455596. 
    • Testa S, Legnani C, Antonucci E, Paoletti O, Dellanoce C, Cosmi B, Pengo V, Poli D, Morandini R, Testa R, Tripodi A, Palareti G, Coordinator of SR. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. Journal of thrombosis and haemostasis : JTH. 2019 Jul;17(7):1064-1072. Epub 2019/04/24. doi:10.1111/jth.14457. Cited in: Pubmed; PMID 31013383. 
    • Testa S, Paoletti O, Legnani C, Dellanoce C, Antonucci E, Cosmi B, Pengo V, Poli D, Morandini R, Testa R, Tripodi A, Palareti G. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. Journal of thrombosis and haemostasis : JTH. 2018 May;16(5):842-848. Epub 2018/03/14. doi:10.1111/jth.14001. Cited in: Pubmed; PMID 29532628. 
    • Suwa M, Morii I, Kino M. Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation- Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration. Circ J. 2019 Apr 25;83(5):991-999. Epub 2019/03/29. doi:10.1253/circj.CJ-18-1282. Cited in: Pubmed; PMID 30918237. 
    • Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbuchel H, External r, Lip GYH, Deneke T, Dagres N, Boriani G, Chao TF, Choi EK, Hills MT, Santos IS, Lane DA, Atar D, Joung B, Cole OM, Field M. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2021 Apr 25. Epub 2021/04/26. doi:10.1093/europace/euab065. Cited in: Pubmed; PMID 33895845. 
    • Seiffge DJ, Traenka C, Polymeris AA, Thilemann S, Wagner B, Hert L, Muller MD, Gensicke H, Peters N, Nickel CH, Stippich C, Sutter R, Marsch S, Fisch U, Guzman R, De Marchis GM, Lyrer PA, Bonati LH, Tsakiris DA, Engelter ST. Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice. J Stroke. 2017 Sep;19(3):347-355. Epub 2017/09/08. doi:10.5853/jos.2017.00395. Cited in: Pubmed; PMID 28877563. 
    • Steiner T, Bohm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Rother J, Schellinger PD, Spannagl M, Veltkamp R. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013 Jun;102(6):399-412. Epub 2013/05/15. doi:10.1007/s00392-013-0560-7. Cited in: Pubmed; PMID 23669868. 
    • Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI, Subcommittee on Control of A. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH. 2016 Mar;14(3):623-7. Epub 2016/02/26. doi:10.1111/jth.13227. Cited in: Pubmed; PMID 26911798. 
    • Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH. 2016 Jun;14(6):1308-13. Epub 2016/06/15. doi:10.1111/jth.13323. Cited in: Pubmed; PMID 27299806. 
    • Piran S, Traquair H, Chan N, Bhagirath V, Schulman S. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. Res Pract Thromb Haemost. 2018 Oct;2(4):684-688. Epub 2018/10/24. doi:10.1002/rth2.12146. Cited in: Pubmed; PMID 30349887. 
    • Siriez R, Dogne JM, Gosselin R, Laloy J, Mullier F, Douxfils J. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory. International journal of laboratory hematology. 2021 Feb;43(1):7-20. Epub 2020/09/19. doi:10.1111/ijlh.13342. Cited in: Pubmed; PMID 32946681. 
       

    Qualiblood website: https://www.qualiblood.eu


    Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.